Relapsing Hematologic Malignancies after Haploidentical Hematopoietic Stem Cell Transplantation

被引：7

作者：

Hu, Yong-Xian ^{[1
]}

Cui, Qu ^{[2
,3
]}

Liang, Bin ^{[4
]}

Huang, He ^{[1
]}

机构：

[1] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Bone Marrow Transplantat Ctr, Hangzhou 310003, Zhejiang, Peoples R China

[2] Jilin Univ, Dept Nucl Med & Biol, China Japan Union Hosp, Changchun 130023, Peoples R China

[3] Univ Tokushima, Inst Hlth Biosci, Dept Med & Bioregulatory Sci, Tokushima 770, Japan

[4] Wenzhou Med Coll, Dept Hematol, Affiliated Hosp 1, Wenzhou, Peoples R China

来源：

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2011年 / 17卷 / 08期

关键词：

Bone marrow; Graft-versus-tumor; Human leukocyte antigen compatibility; Targeted therapy; RISK ACUTE-LEUKEMIA; HLA-MISMATCHED/HAPLOIDENTICAL BLOOD; BONE-MARROW-TRANSPLANTATION; HLA-DPB1 MATCHING STATUS; T-CELLS; ALLOGENEIC TRANSPLANTATION; ANTITHYMOCYTE GLOBULIN; CLINICAL-OUTCOMES; MYELOID-LEUKEMIA; HODGKIN-LYMPHOMA;

D O I：

10.1016/j.bbmt.2011.02.013

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Haploidentical hematopoietic stem cell transplantation (HSCT) is a potentially curative therapeutic regimen that could increase donor availability to nearly 100%. Rapid advances in medical technology and the application of novel drugs mean that most haploidentical HSCT-associated complications can now be prevented or remarkably well controlled, even cured. However, relapsing hematologic malignancy remains a major cause of death in haploidentical HSCT recipients. Haploidentical HSCT should theoretically trigger a more potent graft-versus-tumor effect compared with human leukocyte antigen-identical transplantation, due mainly to the major histocompatibility complex and minor histocompatibility anitigen disparities on donors' immune cells and recipients' tumor cells. The underlying mechanisms of such relapsing hematologic malignancies remain elusive. In this review, we suggest correlating factors and potential mechanisms and examine feasible therapeutic and preventive strategies for relapsing hematologic malignancies after haploidentical HSCT Biol Blood Marrow Transplant 17: 1099-1111 (2011) (C) 2011 American Society for Blood and Marrow Transplantation

引用

页码：1099 / 1111

页数：13

共 96 条

[1] Targeting B cell leukemia with highly specific allogeneic T cells with a public recognition motif [J].

Abrahamsen, I. W. ;

Stronen, E. ;

Walchli, S. ;

Johansen, J. N. ;

Kjellevoll, S. ;

Kumari, S. ;

Komada, M. ;

Gaudernack, G. ;

Tjonnfjord, G. ;

Toebes, M. ;

Schumacher, T. N. ;

Lund-Johansen, F. ;

Olweus, J. .

LEUKEMIA, 2010, 24 (11) :1901-1909

[2] Transplantation of haploidentically mismatched stem cells for the treatment of malignant diseases [J].

Aversa, F ;

Martelli, MF .

SPRINGER SEMINARS IN IMMUNOPATHOLOGY, 2004, 26 (1-2) :155-168

[3] Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402 [J].

Baba, Toshiyuki ;

Sato-Matsushita, Marimo ;

Kanamoto, Akira ;

Itoh, Akihiko ;

Oyaizu, Naoki ;

Inoue, Yusuke ;

Kawakami, Yutaka ;

Tahara, Hideaki .

JOURNAL OF TRANSLATIONAL MEDICINE, 2010, 8

[4] Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes [J].

Barker, Juliet N. ;

Doubrovina, Ekaterina ;

Sauter, Craig ;

Jaroscak, Jennifer J. ;

Perales, Miguel A. ;

Doubrovin, Mikhail ;

Prockop, Susan E. ;

Koehne, Guenther ;

O'Reilly, Richard J. .

BLOOD, 2010, 116 (23) :5045-5049

[5] Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a Phase I clinical study [J].

Barkholt, L. ;

Alici, E. ;

Conrad, R. ;

Sutlu, T. ;

Gilljam, M. ;

Stellan, B. ;

Christensson, B. ;

Guven, H. ;

Bjorkstrom, N. K. ;

Soderdahl, G. ;

Cederlund, K. ;

Kimby, E. ;

Aschan, J. ;

Ringden, O. ;

Ljunggren, H-G ;

Dilber, M. S. .

IMMUNOTHERAPY, 2009, 1 (05) :753-764

[6] CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation [J].

Bashey, Asad ;

Medina, Bridget ;

Corringham, Sue ;

Pasek, Mildred ;

Carrier, Ewa ;

Vrooman, Linda ;

Lowy, Israel ;

Solomon, Scott R. ;

Morris, Lawrence E. ;

Holland, H. Kent ;

Mason, James R. ;

Alyea, Edwin P. ;

Soiffer, Robert J. ;

Ball, Edward D. .

BLOOD, 2009, 113 (07) :1581-1588

[7] Graft-Versus-Leukemia Effect on Infant Lymphoblastic Leukemia Relapsed After Sibling Hematopoietic Stem Cell Transplantation [J].

Boatsman, Erin E. ;

Fu, Cecilia H. ;

Song, Sophie X. ;

Moore, Theodore B. .

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2010, 32 (02) :E57-E60

[8] Chemotherapeutic Drug-Induced ABCG2 Promoter Demethylation as a Novel Mechanism of Acquired Multidrug Resistance [J].

Bram, Eran E. ;

Stark, Michal ;

Raz, Shachar ;

Assaraf, Yehuda G. .

NEOPLASIA, 2009, 11 (12) :1359-U133

[9] Herpes simplex thymidine kinase gene-transduced donor lymphocyte infusions [J].

Burt, RK ;

Drobyski, WR ;

Seregina, T ;

Traynor, A ;

Oyama, Y ;

Keever-Taylor, C ;

Stefka, J ;

Kuzel, TM ;

Brush, M ;

Rodriquez, J ;

Burns, W ;

Tennant, L ;

Link, C .

EXPERIMENTAL HEMATOLOGY, 2003, 31 (10) :903-910

[10] NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biological Considerations of Hematological Relapse following Allogeneic Stem Cell Transplantation Unrelated to Graft-versus-Tumor Effects: State of the Science [J].

Cairo, Mitchell S. ;

Jordan, Craig T. ;

Maley, Carlo C. ;

Chao, Clifford ;

Melnick, Ari ;

Armstrong, Scott A. ;

Shlomchik, Warren ;

Molldrem, Jeff ;

Ferrone, Soldano ;

Mackall, Crystal ;

Zitvogel, Laurence ;

Bishop, Michael R. ;

Giralt, Sergio A. ;

June, Carl H. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (06) :709-728

← 1 2 3 4 5 6 7 8 9 10 →